loading
Moonlake Immunotherapeutics stock is traded at $10.73, with a volume of 3.67M. It is up +4.48% in the last 24 hours and down -79.63% over the past month. MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$10.26
Open:
$10.26
24h Volume:
3.67M
Relative Volume:
1.00
Market Cap:
$681.37M
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-4.6652
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+23.79%
1M Performance:
-79.63%
6M Performance:
-69.28%
1Y Performance:
-78.10%
1-Day Range:
Value
$10.11
$10.95
1-Week Range:
Value
$8.1773
$10.95
52-Week Range:
Value
$5.95
$62.75

Moonlake Immunotherapeutics Stock (MLTX) Company Profile

Name
Name
Moonlake Immunotherapeutics
Name
Phone
41 41 510 8022
Name
Address
DORFSTRASSE 29, ZUG
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
MLTX's Discussions on Twitter

Compare MLTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MLTX
Moonlake Immunotherapeutics
10.73 651.52M 0 -145.21M -140.12M -2.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
407.56 104.55B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.33 60.36B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.46 59.84B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
800.99 49.07B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
330.86 35.16B 4.56B -176.77M 225.30M -1.7177

Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-02-25 Downgrade H.C. Wainwright Buy → Neutral
Oct-01-25 Downgrade Goldman Buy → Neutral
Sep-30-25 Downgrade Citigroup Buy → Neutral
Sep-30-25 Downgrade Wolfe Research Outperform → Underperform
Sep-29-25 Downgrade BTIG Research Buy → Neutral
Sep-29-25 Downgrade Jefferies Buy → Hold
Sep-29-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-29-25 Downgrade Stifel Buy → Hold
Jul-28-25 Initiated Rothschild & Co Redburn Neutral
May-19-25 Upgrade Wolfe Research Peer Perform → Outperform
Mar-18-25 Initiated RBC Capital Mkts Outperform
Jan-17-25 Upgrade Goldman Neutral → Buy
Nov-05-24 Resumed Wedbush Outperform
Aug-26-24 Downgrade Wolfe Research Outperform → Peer Perform
Jun-25-24 Initiated Oppenheimer Outperform
Apr-02-24 Initiated Goldman Neutral
Feb-15-24 Initiated Wolfe Research Outperform
Dec-08-23 Initiated Citigroup Buy
Nov-02-23 Initiated Stifel Buy
Sep-14-23 Downgrade Bryan Garnier Buy → Neutral
Aug-31-23 Initiated Needham Buy
Jun-15-23 Initiated Barclays Equal Weight
May-01-23 Initiated Guggenheim Buy
Mar-22-23 Initiated Wedbush Outperform
Mar-09-23 Initiated BTIG Research Buy
Feb-14-23 Initiated Cantor Fitzgerald Overweight
Feb-02-23 Initiated Bryan Garnier Buy
Nov-11-22 Initiated Jefferies Buy
Aug-25-22 Initiated SVB Leerink Outperform
Jul-21-22 Initiated H.C. Wainwright Buy
Jul-07-22 Initiated Cowen Outperform
View All

Moonlake Immunotherapeutics Stock (MLTX) Latest News

pulisher
01:50 AM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MoonLake ImmunotherapeuticsMLTX - PR Newswire

01:50 AM
pulisher
09:01 AM

How to interpret RSI for MoonLake Immunotherapeutics stockMarket Weekly Review & Weekly Chart Analysis and Trade Guides - newser.com

09:01 AM
pulisher
Oct 12, 2025

Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Oct 12, 2025
pulisher
Oct 11, 2025

Chief Financial Officer of MoonLake Immunotherapeutics Matthias Bodenstedt Buys 1.8% More Shares - Yahoo Finance

Oct 11, 2025
pulisher
Oct 11, 2025

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics - GlobeNewswire

Oct 11, 2025
pulisher
Oct 10, 2025

Why Are MoonLake's (MLTX) Trial Setbacks Raising New Questions About Management Credibility and Regulatory Risks? - simplywall.st

Oct 10, 2025
pulisher
Oct 10, 2025

MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpShould You Buy? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

MLTX SECURITIES NOTICE: MoonLake Immunotherapeutics Securities Fraud Investigation is Pending – Contact BFA Law if You Lost Money - GlobeNewswire

Oct 10, 2025
pulisher
Oct 09, 2025

CFO Makes Bold Move with Major Stock Purchase in MoonLake Immunotherapeutics - TipRanks

Oct 09, 2025
pulisher
Oct 09, 2025

MOONLAKE IMMUNOTHERAPEUTICS REMINDER: Bragar Eagel & - GlobeNewswire

Oct 09, 2025
pulisher
Oct 09, 2025

Insider Stock Purchases: October 09, 2025 - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

MoonLake Immunotherapeutics Stock (MLTX) Opinions on Phase 3 Trial Setback - Quiver Quantitative

Oct 09, 2025
pulisher
Oct 09, 2025

Bodenstedt, MoonLake CFO, buys $98k in MLTX stock By Investing.com - Investing.com Nigeria

Oct 09, 2025
pulisher
Oct 09, 2025

Insider Buying: Matthias Bodenstedt Acquires Shares of MoonLake Immunotherapeutics - GuruFocus

Oct 09, 2025
pulisher
Oct 09, 2025

Bodenstedt, MoonLake CFO, buys $98k in MLTX stock - Investing.com

Oct 09, 2025
pulisher
Oct 09, 2025

BFA Law is Investigating MoonLake Immunotherapeutics (MLTX) for Securities Fraud and Urges Shareholders to Contact the Firm - Newsfile

Oct 09, 2025
pulisher
Oct 09, 2025

Measuring MoonLake Immunotherapeutics’s beta against major indicesFed Meeting & Daily Growth Stock Tips - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny - GlobeNewswire

Oct 09, 2025
pulisher
Oct 08, 2025

MLTX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire

Oct 08, 2025
pulisher
Oct 08, 2025

MLTX INQUIRY NOTICE: MoonLake Immunotherapeutics Hit with - GlobeNewswire

Oct 08, 2025
pulisher
Oct 07, 2025

MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile

Oct 07, 2025
pulisher
Oct 07, 2025

Rosen Law Firm Encourages MoonLake Immunotherapeutics Investors to Inquire About Securities Class Action InvestigationMLTX - Barchart.com

Oct 07, 2025
pulisher
Oct 07, 2025

MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Oct 07, 2025
pulisher
Oct 07, 2025

MOONLAKE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Oct 07, 2025
pulisher
Oct 07, 2025

MLTX ALERT: Levi & Korsinsky Investigates MoonLake Immunotherapeutics on Behalf of Shareholders Who Lost Money - ACCESS Newswire

Oct 07, 2025
pulisher
Oct 07, 2025

Oppenheimer lowers Moonlake Immunotherapeutics stock price target after mixed trial results - Investing.com

Oct 07, 2025
pulisher
Oct 07, 2025

Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Cuts Target Price to $25 - 富途牛牛

Oct 07, 2025
pulisher
Oct 07, 2025

MLTX SHAREHOLDER NOTICE: MoonLake Immunotherapeutics - GlobeNewswire

Oct 07, 2025
pulisher
Oct 07, 2025

MoonLake Immunotherapeutics Investors Should Contact Block - GlobeNewswire

Oct 07, 2025
pulisher
Oct 07, 2025

MLTX Investor News: If You Have Suffered Losses in MoonLake - GlobeNewswire

Oct 07, 2025
pulisher
Oct 06, 2025

MLTX ACTIVE INVESTIGATION: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky Now - ACCESS Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

Levi & Korsinsky Investigates Possible Securities Fraud by MoonLake Immunotherapeutics (MLTX) - ACCESS Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

MLTX Investors Have Opportunity to Join MoonLake Immunotherapeutics Fraud Investigation with the Schall Law Firm - The Malaysian Reserve

Oct 06, 2025
pulisher
Oct 06, 2025

MoonLake Immunotherapeutics Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsMLTX - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 9.9%Should You Buy? - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

What is HC Wainwright’s Forecast for MLTX FY2025 Earnings? - Defense World

Oct 06, 2025
pulisher
Oct 06, 2025

MoonLake Immunotherapeutics Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation - GlobeNewswire

Oct 06, 2025
pulisher
Oct 06, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Investors to Reach Out - ACCESS Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

MoonLake Immunotherapeutics (MLTX): Valuation in Focus After VELA HS Trial Setback and Market Scrutiny - simplywall.st

Oct 06, 2025
pulisher
Oct 06, 2025

Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Benzinga

Oct 06, 2025
pulisher
Oct 06, 2025

Leading vs lagging indicators on MoonLake Immunotherapeutics performance2025 Fundamental Recap & Technical Buy Zone Confirmation - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on - The National Law Review

Oct 06, 2025
pulisher
Oct 06, 2025

Ongoing MoonLake Immunotherapeutics (MLTX) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire

Oct 06, 2025
pulisher
Oct 06, 2025

Combining price and volume data for MoonLake ImmunotherapeuticsRisk Management & Daily Profit Focused Screening - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

What earnings revisions data tells us about MoonLake ImmunotherapeuticsSwing Trade & AI Driven Stock Price Forecasts - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

MoonLake Immunotherapeutics results for Phase 3 VELA-1, VELA-2 trials - MSN

Oct 05, 2025
pulisher
Oct 05, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against MoonLake Immunotherapeutics (MLTX) And Encourages Stockholders to Reach Out - ACCESS Newswire

Oct 05, 2025
pulisher
Oct 05, 2025

ATTENTION MLTX Shareholders: Lost Money on MoonLake Immunotherapeutics? Contact Levi & Korsinsky About Investigation - ACCESS Newswire

Oct 05, 2025
pulisher
Oct 05, 2025

Did MoonLake Immunotherapeutics (MLTX) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire

Oct 05, 2025
pulisher
Oct 05, 2025

The week in pharma: action, reaction and insight – week to October 3 - The Pharma Letter

Oct 05, 2025

Moonlake Immunotherapeutics Stock (MLTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Moonlake Immunotherapeutics Stock (MLTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Chen Bihua
Former 10% Owner
Sep 29 '25
Sale
7.21
6,494,151
46,827,628
2,000,000
Chen Bihua
Former 10% Owner
Sep 30 '25
Sale
6.96
5,827
40,556
1,994,173
Moukheibir Catherine
Director
Jul 03 '25
Option Exercise
0.00
23,500
0
23,500
Moukheibir Catherine
Director
Jul 03 '25
Sale
48.79
23,500
1,146,565
0
$85.13
price up icon 1.59%
$22.83
price up icon 7.21%
$32.80
price up icon 3.03%
$102.59
price up icon 0.56%
$165.04
price up icon 1.60%
biotechnology ONC
$330.86
price up icon 3.39%
Cap:     |  Volume (24h):